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romidepsin.INTRODUCTION
Romidepsin is a histone-deacetylase inhibitor
administered for treatment-refractory mycosis
fungoides. Common side effects include fatigue,
weakness, nausea, and cytopenia. We report a
patient with Sezary syndrome treated with romidep-
sin who developed a reproducible neutrophil-rich
urticarial eruption.CASE REPORT
A 72-year-old Caucasian woman with Sezary
syndrome was treated for 3 years with interferon
alfa-2b and extracorporeal photopheresis. In a span
of 8 weeks between clinic visits, she developed
2.4-cm lymphadenopathy and worsening erythro-
derma. Histology of the surgically excised node
revealed Dutch grade III changes with proliferation
of atypical lymphocytes and partial architectural
effacement. T-cell gene rearrangement studies of
the lymph node revealed the same clone as was
present in the leukemic cells. Her Sezary cell count
abruptly increased in the same time frame from 8.2%
to 50% of the total lymphocytes, and counts
increased from 410 to 4410 cells/L. Positron
emission tomography fluorodeoxyglucose scan
showed avid uptake in axillary, inguinal, and pelvic
lymph nodes, the largest measuring 1.7 cm and
1.8 cm in the left axillae and right inguinal area,
respectively.
Because of disease progression, interferon and
extracorporeal photopheresis were discontinued
and treatment was initiated with romidepsin
(14 mg/m2) on days 1, 8, and 15, along with
bexarotene (150 mg) twice daily. Clinically, she
responded well to romidepsin with resolution of
the erythroderma after the first infusion. However,the Department of Dermatology, University of Texas
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ickless@utsouthwestern.edu.within 5 hours after second infusion, she developed
bright, hot, salmon-pink, nonscaly edematous
nummular patches and plaques in body folds and
on the face, upper aspect of the chest, and back
(Figs 1 and 2). She reported that her skin felt like a
heat rash with minimal pruritus. She had no fevers,
skin pain, lymphadenopathy, mucositis, arthralgia,
transaminitis, neutrophilia, or eosinophilia.
The eruption was treated with desonide 0.05%
ointment applied to the face and triamcinolone 0.1%
ointment applied to the body. Punch biopsy
specimen demonstrated a neutrophilic infiltrate in
the papillary and superficial reticular dermis with
mild spongiosis and no epidermal necrosis (Fig 3).
The eruption began to subside on day 3 postinfusion
and was completely resolved before the next
infusion 1 week later (Fig 4). This reaction recurred
in the same distribution with every subsequent
romidepsin infusion, consistent with an urticarial
fixed drug eruption. Trials of preinfusion and
postinfusion diphenhydramine, dexamethasone,
methylprednisolone, cooling packs, doxycycline,
and dapsone on the day before and day of infusion
failed to modify the development or character of the
reaction. Romidepsin treatment was continued but
gabapentin was added to the regimen with moderate
relief of pruritus. After a period of 4 months, the
eruption was still present and reproducible but was
significantly milder in severity.DISCUSSION
Romidepsin is a novel treatment for mycosis
fungoides that works primarily by binding a zinc
ion needed for histone deacetylase function. Loss of
histone deacetylase promotes apoptosis in rapidly
dividing lymphocyte populations, with a responseJAAD Case Reports 2016;2:261-3.
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Fig 1. Drug eruption on the chest of patient 1 day after
romidepsin infusion.
Fig 2. Drug eruption on the abdomen of patient 1 day
after romidepsin infusion.
Fig 4. Chest of patient 6 days after romidepsin infusion
showing near complete resolution of prior erythematous
rash.
Fig 3. Eruption skin biopsy specimen demonstrating a
neutrophilic infiltration with admixed atypical Sezary cells.
(Hematoxylin-eosin stain; original magnification: 340.)
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Median time to response is 8 weeks and the median
duration of response is between 13 and 15 months.
Mild side effects of nausea and fatigue occur in about
half of patients, and asymptomatic T-wave flattening
occurs in about 80% of patients. Approximately one
quarter of patients can experience cytopenias.1,2
Although 1 patient was noted to develop dermatitis
medicamentosa during phase-II trials, no details
regarding the nature of the eruption were provided.2
Drug-induced urticaria is the second most com-
mon pattern of cutaneous drug eruption, second
only to morbilliform lesions.3 Lesions are typically
pruritic, edematous, and erythematous wheals.
Histologically, there is dermal edema with perivas-
cular and interstitial infiltrates of lymphocytes, eo-
sinophils, and neutrophils.4 ‘‘Neutrophilic urticaria’’
is a term used to describe the 5% to 9%5,6 of urticarial
lesions that show a predominantly neutrophilic
infiltrate on histologic examination. In contrast to
conventional urticaria, neutrophilic urticaria has a
shorter duration, is less pruritic, and responds poorly
to antihistamines, which suggests a pathway that
may be less reliant on mast-cell degranulation
relative to conventional urticaria.6,7
The differential diagnosis for a drug eruption with
a predominantly neutrophilic infiltrate includesneutrophilic urticaria with systemic inflammation
and drug-induced Sweet syndrome. Neutrophilic
urticaria with systemic inflammation is a recently
described entity composed of erythematous macules
clinically and a neutrophilic infiltrate histologically.
However, neutrophilic urticaria with systemic
inflammation can be differentiated from neutrophilic
urticaria by minimal dermal edema, neutrophil
infiltration into the more reticular dermis, leukocy-
toclasia, and presence of systemic inflammation or a
collagen vascular disease, none of which were found
in our patient.8 In drug-induced Sweet syndrome,
erythematous plaques are typically painful or tender
along with a dense neutrophilic infiltrate and fever,
which our patient lacked.3
Our patient developed reproducible urticarial
lesions within 5 hours of each romidepsin infusion,
which would self-resolve over the subsequent
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on biopsy specimen and lack of response to antihis-
tamines suggest a neutrophilic urticarial drug erup-
tion. Although this adverse effect has not
necessitated discontinuation of romidepsin treat-
ment, the pruritus and cosmesis of the rash nega-
tively impact the patient’s quality of life. Clinicians
and patients should be aware of this potential
adverse effect that does not require discontinuation
of the drug unless deemed intolerable by the patient.REFERENCES
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